CCL2 and neoplasm: In multivariate Cox’s regression analysis (adjusted for tumor stage, lymph node stage, molecular subtype), CCL2 positivity remained an independent prognostic marker for OS in the subgroups: pT2 (RR = 4.02; p = 0.002), patients with adjuvant chemotherapy (RR = 2.56; p = 0.018), and in the molecular subtype luminal (RR = 1.97; p = 0.021), and an independent prognostic marker for DSS in the subgroup of patients with adjuvant chemotherapy (RR = 2.48; p = 0.027; Table 3).